Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alcon Inc (NY: ALC )

96.74 +0.05 (+0.05%)
Streaming Delayed Price Updated: 11:11 AM EDT, Oct 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alcon Inc

< Previous 1 2 3 Next >
Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023
From Alcon Inc. Corporate
Via Business Wire
Alcon Reports Fourth Quarter and Full Year 2022 Results
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices
From Alcon Inc. Investors
Via Business Wire
Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism
From Alcon Inc. Investors
Via Business Wire
Alcon to Present at 2023 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Alcon Prices US$1.3 Billion Senior Notes Offering
From Alcon Inc. Investors
Via Business Wire
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
From Alcon Inc. Investors
Via Business Wire
Alcon Reports Third Quarter 2022 Results
From Alcon Inc. Investors
Via Business Wire
Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
From Alcon Inc. Investors
Via Business Wire
Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
From Alcon Inc. Investors
Via Business Wire
Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of 
Via Spotlight Growth
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
From Alcon Inc. Investors
Via Business Wire
Alcon Reports Second Quarter 2022 Results
From Alcon Inc. Investors
Via Business Wire
Football Star Cooper Kupp Encourages Eye Allergy Sufferers to Find the Right Tool for the Job with Pataday
From Alcon Inc. Corporate
Via Business Wire
Alcon Prices EUR 500.0 Million Senior Notes Offering
From Alcon Inc. Investors
Via Business Wire
Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio
From Alcon Inc. Investors
Via Business Wire
Alcon Reports First Quarter 2022 Results
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Results of 2022 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Alcon’s SMARTCataract Demonstrates Enhanced Efficiency and Time Savings for Cataract Surgeries
From Alcon Inc. Corporate
Via Business Wire
Alcon to Deliver Robust Scientific Program at ASCRS 2022
From Alcon Inc. Investors
Via Business Wire
Actress Kate Walsh Teams Up with Eye Care Leader Alcon to Inspire Millions of Dry Eye Sufferers to Make Every Look Count
From Alcon Inc. Corporate
Via Business Wire
Actress Kate Walsh Teams Up with Eye Care Leader Alcon to Inspire Millions of Dry Eye Sufferers to Make Every Look Count
From Alcon Inc. Corporate
Via Business Wire
Alcon Publishes Agenda for 2022 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Alcon Reports Fourth Quarter and Full Year 2021 Results
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe
From Alcon Inc. Investors
Via Business Wire
Alcon to Launch DAILIES TOTAL1 Contact Lenses in the U.S. for Patients with Astigmatism
From Alcon Inc. Investors
Via Business Wire
Alcon Completes Acquisition of Ivantis, Inc., Bringing Hydrus Microstent into Its Global Surgical Portfolio
From Alcon Inc. Investors
Via Business Wire
Alcon Reports Third Quarter 2021 Results
From Alcon Inc. Investors
Via Business Wire
Alcon Unveils Latest Evolution of Cataract Integration and Connectivity at AAO 2021
From Alcon Inc. Corporate
Via Business Wire
Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio
From Alcon Inc. Investors
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.